By Dave Bender
Biopharmaceutical firm NasVax has signed a deal with Swiss pharma giant Norvartis to develop new vaccines together, including influenza-fighting strains. "What's significant is that Novartis is one of the five largest vaccine companies in the world," Dr. Ronald Ellis, NasVax senior vice president and chief technical officer, tells ISRAEL21c, "and they found it attractive to work with us." Read the rest.
Biopharmaceutical firm NasVax has signed a deal with Swiss pharma giant Norvartis to develop new vaccines together, including influenza-fighting strains. "What's significant is that Novartis is one of the five largest vaccine companies in the world," Dr. Ronald Ellis, NasVax senior vice president and chief technical officer, tells ISRAEL21c, "and they found it attractive to work with us." Read the rest.
No comments:
Post a Comment